As Promised, Rosetta Expands Dx Pipeline With Trio of Cancer, Women’s Health Tests
June 19, 2008
As Promised, Rosetta Expands Dx Pipeline With Trio of Cancer, Women’s Health Tests
Rosetta Genomics said that the new diagnostics will be available between 2009 and 2010, and will be developed and commercialized through its soon-to-be acquired CLIA laboratory.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tools & Techniques: TALENs for miRNA Manipulation; CLASH for miRNA-Target Analysis; and More
May 21, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 21, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 21, 2013 / Gene Silencing News - Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 20, 2013 / Gene Silencing News